share_log

Irene Becklund Sells 10,668 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Irene Becklund Sells 10,668 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

艾琳·貝克倫德出售Hims&Hers Health,Inc.(紐約證券交易所代碼:HIMS)股票10,668股
Defense World ·  2022/09/23 06:12

Hims & Hers Health, Inc. (NYSE:HIMS – Get Rating) insider Irene Becklund sold 10,668 shares of the stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $5.68, for a total value of $60,594.24. Following the completion of the transaction, the insider now directly owns 6,978 shares in the company, valued at approximately $39,635.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Hims&Hers Health,Inc.(紐約證券交易所代碼:HIMS-GET Rating)內部人士艾琳·貝克倫德在9月20日(星期二)的一次交易中出售了10,668股該股。這些股票的平均價格為5.68美元,總價值為60,594.24美元。交易完成後,這位內部人士現在直接擁有該公司6978股,價值約39635.04美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接.

Irene Becklund also recently made the following trade(s):

艾琳·貝克倫德最近還做了以下交易:

Get
到達
Hims & Hers Health
他和她的健康
alerts:
警報:
  • On Friday, September 9th, Irene Becklund sold 11,002 shares of Hims & Hers Health stock. The shares were sold at an average price of $6.64, for a total value of $73,053.28.
  • On Tuesday, July 5th, Irene Becklund sold 19,331 shares of Hims & Hers Health stock. The shares were sold at an average price of $5.00, for a total value of $96,655.00.
  • 9月9日,星期五,艾琳·貝克倫德出售了11,002股Hims&Her Health股票。這些股票的平均價格為6.64美元,總價值為73,053.28美元。
  • 7月5日,星期二,艾琳·貝克倫德出售了19331股Hims&Her Health股票。這些股票的平均價格為5美元,總價值為96,655.00美元。

Hims & Hers Health Trading Down 3.7 %

HIS&HERS健康降價3.7%

Shares of HIMS opened at $5.47 on Friday. Hims & Hers Health, Inc. has a fifty-two week low of $2.72 and a fifty-two week high of $9.19. The firm has a 50-day simple moving average of $6.22 and a 200-day simple moving average of $5.10.

上週五,HIM的股價開盤報5.47美元。Hims&Hers Health,Inc.的股價為52周低點2.72美元,52周高點9.19美元。該公司的50日簡單移動均線切入位在6.22美元,200日簡單移動均線切入位在5.10美元。

Hims & Hers Health (NYSE:HIMS – Get Rating) last announced its earnings results on Monday, August 8th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). Hims & Hers Health had a negative net margin of 22.22% and a negative return on equity of 23.24%. The business had revenue of $113.60 million during the quarter, compared to the consensus estimate of $103.89 million. During the same quarter in the prior year, the firm earned ($0.08) earnings per share. The business's quarterly revenue was up 89.0% compared to the same quarter last year. Equities research analysts predict that Hims & Hers Health, Inc. will post -0.36 earnings per share for the current fiscal year.
Hims&Hers Health(紐約證券交易所代碼:HIMS-GET Rating)上一次公佈收益結果是在8月8日星期一。該公司公佈了本季度每股收益(0.10美元),超過了普遍預期的(0.10美元)。Hims&Hers Health的淨利潤率為負22.22%,股本回報率為負23.24%。該業務本季度的收入為1.136億美元,而普遍預期為1.0389億美元。去年同期,該公司每股收益為0.08美元。與去年同期相比,該業務的季度收入增長了89.0%。股票研究分析師預計,Hims&Hers Health,Inc.將公佈本財年每股收益為0.36美元。

Wall Street Analyst Weigh In

華爾街分析師也加入進來

HIMS has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $7.00 to $8.00 in a report on Wednesday, August 10th. Guggenheim raised their price objective on Hims & Hers Health to $12.00 in a report on Monday, August 15th. Credit Suisse Group raised their price objective on Hims & Hers Health from $7.00 to $8.00 and gave the stock an "outperform" rating in a report on Wednesday, August 10th. Piper Sandler dropped their price objective on Hims & Hers Health from $8.00 to $6.00 and set an "overweight" rating on the stock in a report on Thursday, May 26th. Finally, SVB Leerink raised their price objective on Hims & Hers Health from $4.00 to $5.00 and gave the stock an "underperform" rating in a report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of "Hold" and an average price target of $7.38.

HIM一直是最近幾份分析師報告的主題。德意志銀行Aktiengesellschaft在8月10日星期三的一份報告中將其對Hims&Hers Health的目標價從7.00美元上調至8.00美元。古根海姆在8月15日星期一的一份報告中將他們對Hims&Hers Health的目標價格上調至12.00美元。瑞士信貸集團將Hims&Hers Health的目標價從7.00美元上調至8.00美元,並在8月10日(星期三)的一份報告中給出了該股“跑贏大盤”的評級。派珀·桑德勒在5月26日星期四的一份報告中將他們對Hims&Hers Health的目標價從8.00美元下調至6.00美元,並對該股設定了“增持”評級。最後,SVB Leerink將Hims&Hers Health的目標價從4.00美元上調至5.00美元,並在8月9日(星期二)的一份報告中給出了該股表現不佳的評級。一位研究分析師對該股的評級為賣出,三位分析師給出了持有評級,四位分析師給出了該公司股票的買入評級。根據MarketBeat.com的數據,Hims&Hers Health的共識評級為持有,平均目標價為7.38美元。

Institutional Investors Weigh In On Hims & Hers Health

機構投資者關注Hims&His的健康狀況

Several hedge funds have recently made changes to their positions in HIMS. Raymond James & Associates acquired a new stake in Hims & Hers Health in the fourth quarter valued at about $205,000. HighTower Advisors LLC lifted its position in Hims & Hers Health by 14.4% in the fourth quarter. HighTower Advisors LLC now owns 31,761 shares of the company's stock valued at $209,000 after purchasing an additional 3,998 shares during the period. Teacher Retirement System of Texas lifted its position in Hims & Hers Health by 25.6% in the fourth quarter. Teacher Retirement System of Texas now owns 14,808 shares of the company's stock valued at $97,000 after purchasing an additional 3,022 shares during the period. Qube Research & Technologies Ltd acquired a new stake in Hims & Hers Health in the fourth quarter valued at about $237,000. Finally, PEAK6 Investments LLC lifted its position in Hims & Hers Health by 18.3% in the fourth quarter. PEAK6 Investments LLC now owns 138,866 shares of the company's stock valued at $910,000 after purchasing an additional 21,526 shares during the period. Institutional investors and hedge funds own 43.41% of the company's stock.

幾家對衝基金最近改變了他們在HIM的頭寸。Raymond James&Associates在第四季度收購了Hims&Hers Health的新股份,價值約20.5萬美元。HighTower Advisors LLC在第四季度將其在Hims&Hers Health的頭寸提高了14.4%。HighTower Advisors LLC在此期間又購買了3998股,現在擁有31,761股該公司股票,價值20.9萬美元。德克薩斯州教師退休系統在第四季度將其在Hims&Hers Health的地位提高了25.6%。德克薩斯州教師退休系統在此期間額外購買了3,022股,現在擁有14,808股該公司股票,價值97,000美元。Qube Research&Technologies Ltd在第四季度收購了Hims&Hers Health的新股份,價值約23.7萬美元。最後,PEAK6 Investments LLC在第四季度將其在Hims&Hers Health的頭寸提高了18.3%。Peak6 Investments LLC在此期間又購買了21,526股,現在擁有138,866股該公司股票,價值91萬美元。機構投資者和對衝基金持有該公司43.41%的股票。

Hims & Hers Health Company Profile

他和她的健康公司簡介

(Get Rating)

(獲取評級)

Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.

Hims&Hers Health,Inc.運營着一個多專業遠程醫療平臺,將消費者與有執照的醫療保健專業人員聯繫起來。該公司提供一系列健康和健康產品和服務,可在其網站和移動應用程序上直接由客户購買。它還提供定期的處方藥和醫療保健提供者的持續護理;以及非處方藥和設備產品、化粧品和補充劑產品,主要側重於健康、性健康和健康、皮膚護理和頭髮護理。

Featured Stories

專題報道

  • Get a free copy of the StockNews.com research report on Hims & Hers Health (HIMS)
  • The Institutions Hold On To Darden Restaurants International
  • What Steelcase's Earnings Say About the Return to the Office?
  • These 3 Big Dividend Payers Also Boast Strong Price Growth
  • Is The Golden Age Of Homebuilding Already Over?
  • Natural Gas Prices Continue To Rally, These Stocks Should Benefit
  • 免費獲取StockNews.com關於他和她的健康的研究報告(HIMS)
  • 這些機構持有達頓餐飲國際公司的股份
  • 斯蒂爾凱斯的收益説明瞭他重返辦公室的原因嗎?
  • 這三大股利支付者也擁有強勁的價格增長
  • 住房建設的黃金時代已經結束了嗎?
  • 天然氣價格繼續回升,這些股票應該會受益

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.

接受《健康日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Hims&Hers Health和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論